2,084
+2.86%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ASKA Pharmaceutical Holdings Co
Its shares trade on Tokyo Stock Exchange under the ticker 4886.T. It has been listed since 1 April 2021. In the fiscal year to 31 March 2026, it reported revenue of ¥71.13bn and net income of ¥5.42bn. At that date it held total assets of ¥112.01bn and shareholders' equity of ¥69.99bn.
ASKA Pharmaceutical Holdings Co., Ltd. engages in the management of its group companies which are involved in the manufacture and sale of pharmaceuticals, quasi-drugs, food, veterinary drugs, feeds, feed additives, and medical devices. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2021-04-01. The firm mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Apr 2021
- Employees
- 747
- Website
- aska-pharma-hd.co.jp ↗
Leadership
Pay as last reported
- Mr. Takashi YamaguchiPresident, Chairman of Subsidiary, Representative Director, since 2021
- Mr. Atsushi MaruoSenior Managing Director, Representative Director, since 2021
- Mr. Sohta YamaguchiSenior Managing Director, President of Subsidiary, Representative Director, since 2021
- Ms. Maiko MoriManaging Executive Officer, Director, since 2022
- Mr. Fumiyoshi YamaguchiManaging Executive Officer, President of Subsidiary, Director, since 2022
- Mr. Kiyohiko TamuraManaging Executive Officer, Chief Director of Group Business Administration
- Mr. Kunihiro ChikuExecutive Officer
- Mr. Junichi SaitoExecutive Officer, President of Subsidiary
- Mr. Minoru AwabayashiIndependent Director
- Mr. Yasuji EnokidoIndependent Director
- Ms. Kanae KaritaIndependent Director
- Mr. Yasunori YoshimuraIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ASKA Pharmaceutical Holdings employs 747 full-time employees in Minato-ku, Tokyo.
- The company operates two business segments: Pharmaceuticals and Others.
- ASKA's business includes manufacturing and selling pharmaceuticals, medical devices, and veterinary drugs.
Weaknesses
- ASKA's IPO was on 1 April 2021, which is a recent listing.
- The company's headquarters is in Minato-ku, Tokyo, limiting regional presence.
- ASKA's business segments are limited to Pharmaceuticals and Others.
Opportunities
- ASKA can expand its veterinary drug segment in Japan's growing market.
- The Others segment offers clinical testing services, which could grow with healthcare demand.
- ASKA's medical device sales may increase with aging population needs.
Threats
- ASKA faces competition from established pharmaceutical companies in Japan.
- The Japanese healthcare market is highly regulated, posing compliance challenges.
- ASKA's recent IPO may lead to financial pressures for growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.